Crizotinib (Crizotinib)
Overview of Crizotinib
Crizotinib is a newly initially approved drug by the FDA. Crizotinib is an oral tyrosine kinase inhibitor which is used for the treatment of patient with locally advanced or metastatic non small cell lung cancer that has to be positive as an anaplastic lymphoma kinase (ALK) which is a FDA approved test. The treatment with crizotinib is response rate based. Crizotinib has demonstratedconcentration dependent inhibition of ALK & c-met phosphorylation in cell based assay using tumor cell line and demonstrated antitumor activity.
Indication of Crizotinib
Crizotinib is primarily indicated in conditions like Non small cell lung cancer.
Contraindication of Crizotinib
No data regarding the contra indications of Crizotinib is available.
Side Effects of Crizotinib
The symptomatic adverse reactions produced by Crizotinib are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Diarrhea, Constipation, Yision disorder, Yomiting.
Precautions of Crizotinib
Precautions